MALVERN, Pa., Sept. 10, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that two presentations related to plantar fibromatosis (PFI) and plantar fasciitis ...
MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during ...
DUBLIN, March 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in ...
MALVERN, Pa. - Endo, Inc. (OTCQX:NDOI), a $1.6 billion pharmaceutical company currently trading near its 52-week low, announced Thursday that it is presenting three studies related to plantar ...
MALVERN, Pa., Sept. 10, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that two presentations related to plantar fibromatosis (PFI) and plantar fasciitis ...